Table 1. Clinical and biochemical features of the COVID-19 associated SAT cases and the present case.
| Manuscript | Country | Patient | Time from COVID-19 onset to SAT onset (days) | Laboratory markers at the time of diagnosis | Normal ranges | Initial therapy |
|---|---|---|---|---|---|---|
| Abreu R et al. (2) | Brazil | F, 34 y | 28 | N.A. | N.A. | Prednisone 15 mg/d |
| Abreu R et al. (2) | Brazil | F, 34 y | 10 | FT4 1.8 ng/dL | N.A. | Prednisone |
| Abreu R et al. (2) | Brazil | F, 39 y | 26 | N.A. | N.A. | N.A. |
| Álvarez Martín MC et al. (3) | Spain | F, 46 y | Asymptomatic COVID-19, during SAT, SARS-CoV-2 serology positive | TSH 0.11 mIU/mL FT4 2.18 ng/dL ESR 68 mm/h |
TSH 0.55-4.78 mIU/mL FT4 0.89-1.76 ng/dL |
Prednisone 40 mg/d |
| Asfuroglu Kalkan E et al. (4) | Turkey | F, 41 y | Asymptomatic COVID-19, during SAT, SARS-CoV-2 PCR positive | TSH < 0.008 mIU/L FT4 25.7 pmol/L FT3 7.7 pmol/L CRP 101 mg/L ESR 134 mm/h |
TSH < 0.008 mIU/L FT4 12-21 pmol/L FT3 3.1-6.8 pmol/L |
Hydroxychloroquine 200 mg/d Prednisone 16 mg/d |
| Brancatella A et al. (1) | Italy | F, 18 y | 19 | TSH < 0.04 mIU/L FT4 27.2 nmol/L FT3 8.7 pmol/L CRP 6.9 mg/L ESR 90 mm/h |
TSH 0.5-4.1 mIU/L FT4 11-23 nmol/L FT3 4.6-8.4 pmol/L |
Prednisone 25 mg/d |
| Brancatella A et al. (5) | Italy | F, 38 y | 16 | TSH 0.1 mIU/mL FT4 29.3 nmol/L FT3 8.0 pmol/L CRP 11.2 mg/L ESR 74 mm/h |
TSH 0.4-4.5 mIU/mL FT4 6-16 nmol/L FT3 2.3-4.2 pmol/L |
Prednisone 25 mg/d |
| Brancatella A et al. (5) | Italy | F, 29 y | 30 | TSH < 0.01 mIU/mL FT4 31.8 nmol/L FT3 8.9 pmol/L CRP 7.9 mg/L ESR 110 mm/h |
TSH 0.4-4.5 mIU/mL FT4 6-16 nmol/L FT3 2.3-4.2 pmol/L |
Prednisone 25 mg/d propranolol 40 mg/d |
| Brancatella A et al. (5) | Italy | F, 29 y | 36 | N.A. | N.A. | Ibuprofen 600 mg/d |
| Brancatella A et al. (5) | Italy | F, 46 y | 20 | TSH < 0.01 mIU/mL FT4 27.8 nmol/L FT3 6.9 pmol/L CRP 8 mg/L |
TSH 0.4-4.5 mIU/mL FT4 6-16 nmol/L FT3 2.3-4.2 pmol/L |
Prednisone 25 mg/d |
| Campos-Barrera E et al. (6) | Mexico | F, 37 y | 30 | TSH undetectable FT4 1.6 ng/dL CRP 66 mg/L ESR 72 mm/h |
N.A. | N.A. |
| Chakraborty U et al. (7) | India | M, 58 y | During SAT, SARS-CoV-2 PCR positive | TSH < 0.005 mIU/L FT4 20.11 ug/dL FT3 2.88 ng/mL CRP 16.6 mg/L ESR 110 mm/h |
TSH 0.27-4.2 mIU/L FT4 5.10-14.1 ug/dL FT3 0.80-2.0 ng/mL |
Prednisolone 30 mg/d propranolol 40 mg/d |
| Chong WH et al. (8) | USA | M, 37 y | 30 | TSH 0.01 mIU/L FT4 2.3 ng/dL CRP 14 mg/L ESR 31 mm/h |
TSH 0.4-4.5 mIU/L FT4 0.6-1.3 ng/dL |
NSAID |
| Davoodi et al. (9) | Iran | M, 33 y | During SAT, SARS-CoV-2 PCR positive | TSH < 0.001 mIU/L tT4 23.1 ug/dL tT3 236 ng/dL CRP 37.9 mg/L ESR 84 mm/h |
TSH 0.5-5.0 mIU/L tT4 4-11 ug/dL tT3 75-195 ng/dL CRP <10 mg/L ESR <15 mm/h |
Dexamethasone 12 mg/d then prednisone 25 mg/d |
| Dworakowska et al. (10) | UK | F, 57 y | appr. 60 | anti-TPO, anti-Tg: positive | N.A. | Ibuprofen, paracetamol |
| Ippolito S et al. (11) | Italy | F, 69 y | 5, during SAT, SARS-CoV-2 PCR positive | TSH 0.08 mIU/L FT4 24.6 pg/mL FT3 5.5 pg/mL |
TSH 0.27-4.2 mIU/L FT4 0.3-17 pg/mL FT3 2-4.4 pg/mL |
Methimazol, methylprednisolone 40 mg/d then prednisone 25 mg/d |
| Khatri A et al. (12) | USA | F, 41 y | 28 | TSH < 0.008 mIU/L TT4 222.91 nmol/L CRP 36.4 mg/L ESR 107 mm/h |
TSH 0.7-4.2 mIU/L TT4 59.34-154.8 nmol/L |
Ibuprofen 1,800 mg/d, prednisone 40 mg/d |
| Mattar SAM et al. (13) | Singapore | M, 34 y | 9, during SAT, SARS-CoV-2 PCR positive | TSH < 0.01 mIU/L FT4 41.8 pmol/L FT3 13.4 pmol/L CRP 122 mg/L |
TSH 0.65-3.70 mIU/L FT4 8.8-14.4 pmol/L FT3 3.2-5.3 pmol/L |
Prednisone 20 mg/d, atenolol 25 mg/d |
| Mehmood MA et al. (14) | USA | F, 29 y | 49 | TSH 0.01 mIU/L FT4 4.4 ng/L FT3 374 ng/L CRP 44 mg/L ESR 84 mm/h |
TSH N.A. FT4 0.6-1.3 ng/L FT3 80-150 ng/L |
Prednisone 20 mg/d, atenolol 25 mg/d |
| Muller I et al. (15) | Italy | M, 24 y | During SAT, SARS-CoV-2 PCR positive | TSH 0.33 mIU/L FT4 9.6 pmol/L FT3 4.0 pmol/L CRP 10 mg/L |
TSH 0.28-4.3 mIU/L FT4 10.3-21.9 pmol/L FT3 3.1-7.7 pmol/L |
N.A. |
| Muller I et al. (15) | Italy | F, 59 y | During SAT, SARS-CoV-2 PCR positive | TSH 0.4 mIU/L FT4 16.6 pmol/L FT3 2.3 pmol/L CRP 233 mg/L |
TSH 0.28-4.3 mIU/L FT4 10.3-21.9 pmol/L FT3 3.1-7.7 pmol/L |
N.A. |
| Muller I et al. (15) | Italy | M, 66 y | During SAT, SARS-CoV-2 PCR positive | TSH 0.43 mIU/L FT4 22.8 pmol/L CRP 52 mg/L |
TSH 0.28-4.3 mIU/L FT4 10.3-21.9 pmol/L FT3 3.1-7.7 pmol/L |
N.A. |
| Ruano R et al. (16) | Spain | F, 28 y | 29 | TSH < 0.001 mIU/L FT4 37.5 pmol/L CRP 176 mg/L |
TSH 0.38-5.33 mIU/L FT4 7.0-16.0 pmol/L |
Paracetamol 1 g/8 h, aspirin 500 mg/d, propranolol 40 mg/d |
| Ruggeri RM et al. (17) | Italy | F, 43 y | cca. 45 | TSH 0.006 mIU/L FT4 2.69 ng/dL FT3 7.03 pg/mL |
TSH 0.27-4.2 mIU/L FT4 0.7-1.48 ng/dL FT3 1.71-3.71 pg/mL |
prednisone 25 mg/d |
| San Juan MDJ et al. (18) | Philippines | F, 47 y | During SAT, SARS-CoV-2 PCR positive | TSH 0.05 mIU/mL FT4 1.68 pg/mL CRP 5.09 mg/dL |
TSH 0.47-4.68 mIU/mL FT4 0.78-2.19 pg/mL |
NSAID |
| Seyed Resuli A et al. (19) | Turkey | F, 32 y | During SAT, SARS-CoV-2 PCR positive | FT4 26.8 pmol/L FT3 8.4 pmol/L ESR 65 mm/h |
FT4 12-22 pmol/L FT3 3-6 pmol/L |
Aspirin 3 g/d |
| Seyed Resuli A et al. (19) | Turkey | F, 25 y | During SAT, SARS-CoV-2 PCR positive | FT4 28.1 pmol/L FT3 9.6 pmol/L ESR 58 mm/h |
FT4 12-22 pmol/L FT3 3-6 pmol/L |
Aspirin 3 g/d |
| Seyed Resuli A et al. (19) | Turkey | F, 45 y | During SAT, SARS-CoV-2 PCR positive | FT4 43.1 pmol/L FT3 14.2 pmol/L ESR 70 mm/h |
FT4 12-22 pmol/L FT3 3-6 pmol/L |
Aspirin 3 g/d, prednisolone 1 mg/kg/d |
| Seyed Resuli A et al. (19) | Turkey | F, 29 y | During SAT, SARS-CoV-2 PCR positive | FT4 38.1 pmol/L FT3 11.3 pmol/L ESR 65 mm/h |
FT4 12-22 pmol/L FT3 3-6 pmol/L |
Aspirin 3 g/d |
| Seyed Resuli A et al. (19) | Turkey | F, 21 y | During SAT, SARS-CoV-2 PCR positive | FT4 43.5 pmol/L FT3 16.2 pmol/L ESR 80 mm/h |
FT4 12-22 pmol/L FT3 3-6 pmol/L |
Aspirin 3 g/d, prednisolone 1 mg/kg/d |
| Sohrabpour S et al. (20) | Iran | F, 26 y | N.A. | TSH 0.07 mIU/L FT4 19.5 pmol/L FT3 18.9 pmol/L CRP 28 mg/L ESR 70 mm/h |
TSH 0.4-4.0 mIU/L FT4 12-21 pmol/L FT3 3.1-6.8 pmol/L |
Prednisone 25 mg/d |
| Sohrabpour S et al. (20) | Iran | F, 37 y | N.A. | TSH < 0.01 mIU/L FT4 2.3 pmol/L FT3 25.4 pmol/L CRP 38 mg/L ESR 56 mm/h |
TSH 0.4-4.0 mIU/L FT4 12-21 pmol/L FT3 3.1-6.8 pmol/L |
Prednisone 25 mg/d |
| Sohrabpour S et al. (20) | Iran | M, 35 y | N.A. | TSH 0.12 mIU/L FT4 24.7 pmol/L FT3 19.3 pmol/L CRP 18 mg/L ESR 45 mm/h |
TSH 0.4-4.0 mIU/L FT4 12-21 pmol/L FT3 3.1-6.8 pmol/L |
Prednisone 25 mg/d |
| Sohrabpour S et al. (20) | Iran | F, 41 y | N.A. | TSH < 0.01 mIU/L FT4 21.9 pmol/L FT3 23.7 pmol/L CRP 43 mg/L ESR 83 mm/h |
TSH 0.4-4.0 mIU/L FT4 12-21 pmol/L FT3 3.1-6.8 pmol/L |
Prednisone 25 mg/d |
| Sohrabpour S et al. (20) | Iran | M, 52 y | N.A. | TSH 0.17 mIU/L FT4 26.7 pmol/L FT3 21.6 pmol/L CRP 51 mg/L ESR 76 mm/h |
TSH 0.4-4.0 mIU/L FT4 12-21 pmol/L FT3 3.1-6.8 pmol/L |
Prednisone 25 mg/d |
| Sohrabpour S et al. (20) | Iran | F, 34 y | N.A. | TSH 0.23 mIU/L FT4 18.4 pmol/L FT3 18.1 pmol/L CRP 23 mg/L ESR 39 mm/h |
TSH 0.4-4.0 mIU/L FT4 12-21 pmol/L FT3 3.1-6.8 pmol/L |
Prednisone 25 mg/d |
| Hajósi-Kalcakosz Sz et al. | Hungary | F, 31 y | 35 | TSH 0.046 uIU/mL FT4 1.60 ng/dL FT3 4.10 pg/mL CRP 16.9 mg/L ESR 34 mm/h |
TSH 0.35-4.94 uIU/mL FT4 0.7-1.48 ng/dL FT3 1.71-3.71 pg/mL |
Methylprednisolone 32 mg/d |
Abbreviations: appr.: approximately; CRP: C-reactive protein; d: day; ESR: erythrocyte sedimentation rate; F: female, FT3: free triiodothyronine; FT4: free thyroxine; M: male; N.A.: not available; SAT: subacute thyroiditis; TSH: thyroid stimulating hormone; TT4: total thyroxine; y: year.